## EXAMINER'S AMENDMENT

Claims 14-16, 27-29, 79, and 80 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 46-62, 67-71, and 81-95, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, **the restriction requirement as set forth in the Office action mailed on December 18, 2008 is hereby withdrawn**. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Rachel Mejdrich, applicant's representative, on March 18, 2011.

The application has been amended as follows:

The claims have been amended to read:

1.- 13. (Canceled)

14. (Previously Presented) An isolated polypeptide up to 12 amino acids in length comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 14-19.

15. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

16. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 19.

17.-26. (Canceled)

27. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 14.

28. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 15.

29. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 16.

30.-45. (Canceled)

46. (Currently Amended) A method for treating a subject suffering from ~~or susceptible to~~ a MUC-1 tumor comprising administering to a subject at least one polypeptide of claim 14, such that the subject is treated.

47. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

48. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 19.

49. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 14.

50. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 15.

51. (Currently Amended) A method for treating a subject suffering from ~~or susceptible to~~ a MUC- 1 tumor comprising: isolating dendritic cells from a subject suffering from cancer; treating the dendritic cells with at least one polypeptide of claim 14; and, administering the treated dendritic cells to the subject, such that the subject is treated.

52. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

53. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 19.

54. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.

55. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 15.

56. (Previously Presented) A method for generating an immune response to a weakly immunogenic antigen comprising administering to a subject at least one polypeptide of claim 14 fused to a weak immunogen.

57. (Previously Presented) The method of claim 56, wherein the weak immunogen is a differentiation antigen.

58. (Previously Presented) The method of claim 56, wherein the weak immunogen is a tumor antigen.

59. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 19.

60. (Previously Presented) The method of claim 59, wherein the polypeptide is fused to a carcinoembryonic antigen.

61. (Previously Presented) The method of claim 59, wherein the polypeptide is fused to a viral antigen.

62. (Previously Presented) The method of claim 59, wherein the polypeptide is fused to a self-antigen.

63.-66. (Canceled)

67. (Currently Amended) A method for treating a subject suffering from ~~or susceptible to~~ a MUC- 1 tumor comprising: isolating dendritic cells from a subject suffering from cancer; treating the dendritic cells with at least one polypeptide of claim 14; activating peripheral blood mononuclear cells with the treated dendritic cells; administering the activated PBMC cells to the subject.

68. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

69. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 19.

70. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.

71. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 15.

72.-78. (Canceled)

79. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 17.

80. (Previously Presented) The isolated polypeptide of claim 14, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 18.

81. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 16.

82. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 17.

83. (Previously Presented) The method of claim 46, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 18.

84. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.

85. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 17.

86. (Previously Presented) The method of claim 51, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.

87. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

88. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 14.

89. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 15.

90. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 16.

91. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 17.

92. (Previously Presented) The method of claim 56, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 18.

93. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.

94. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 17.

95. (Previously Presented) The method of claim 67, wherein dendritic cells are treated with a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNE GUSSOW whose telephone number is (571)272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Misook Yu can be reached on (571) 272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anne M. Gussow
March 21, 2011

/Anne M. Gussow/
Primary Examiner, Art Unit 1643